Associated Genetic Biomarkers
CTNNA3 is altered in 0.17% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast neoplasm, breast invasive lobular carcinoma, and ganglioglioma having the greatest prevalence of alterations .
The most common alterations in CTNNA3 are CTNNA3 Mutation (1.45%), CTNNA3 Amplification (0.70%), CTNNA3 Loss (0.54%), CTNNA3 I411V (0.08%), and CTNNA3 M435V (0.08%) .
CTNNA3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CTNNA3 status as an inclusion criterion, 1 is phase 2/phase 3 (1 open).
Trials with CTNNA3 status in the inclusion eligibility criteria most commonly target medulloblastoma .
The most frequent alterations to serve as inclusion eligibility criteria are CTNNA3 Expression and CTNNA3 Mutation .
Radiation therapy is the most frequent therapy in trials with CTNNA3 as an inclusion criteria .
Significance of CTNNA3 in Diseases
CTNNA3 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNA3 status and medulloblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.